Evidence map›Paper›PMID 39114842›Full record

ArticleClinical case reports2024

Neoadjuvant immunotherapy leads to complete pathologic response in locally advanced colon cancer.

Lyndsey Sandow, Liana Tsikitis, Charles D Lopez, Brian Brinkerhoff, Adel Kardosh, Guillaume Pegna, Emerson Y Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lyndsey SandowDepartment of Medicine Oregon Health and Science University Portland Oregon USA.ORCID https://orcid.org/0009-0008-8149-5442
Liana TsikitisDivision of Gastrointestinal and General Surgery, Department of General Surgery Oregon Health and Science University Portland Oregon USA.
Charles D LopezDivision of Hematology and Medical Oncology Oregon Health and Science University, Knight Cancer Institute Portland Oregon USA.
Brian BrinkerhoffDepartment of Pathology Oregon Health and Science University Portland Oregon USA.
Adel KardoshDivision of Hematology and Medical Oncology Oregon Health and Science University, Knight Cancer Institute Portland Oregon USA.
Guillaume PegnaDivision of Hematology and Medical Oncology Oregon Health and Science University, Knight Cancer Institute Portland Oregon USA.
Emerson Y ChenDivision of Hematology and Medical Oncology Oregon Health and Science University, Knight Cancer Institute Portland Oregon USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy is considered first line in patients with dMMR metastatic colorectal cancer (CRC). Recent studies have also shown promising results with neoadjuvant immunotherapy in locally advanced CRC. We report a case in which neoadjuvant immunotherapy with pembrolizumab resulted in complete pathologic response at time of resection as well as saved the patient the morbidity associated with a hepatectomy. We also completed a scoping review of the literature which suggests promising tumor responses with treatment in dMMR CRC. Further randomized control trials to determine the magnitude of response and optimal regimen are needed.

Indexed as

colon cancercomplete pathologic responseimmunotherapypembrolizumab

Identifiers

PMID39114842
PMCPMC11303659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.